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Abstract
Antibodies against conserved epitopes on HIV-1 envelope glycoproteins (Env), such as the gp120 CD4-binding site (CD4bs),
could contribute to protection against HIV-1. Env-based immunogens inducing such a response could be a major
component of future anti-HIV-1 strategies. In this proof-of-concept study we describe the generation of two anti-idiotype
(AI) murine antibodies mimicking the CD4bs epitope. Sera were collected from long-term non-progressor patients to obtain
CD4bs-directed IgG, through sequential purification steps. The purified IgG were then used as Fab fragments to immunize
mice for hybridoma generation. Two hybridomas (P1 and P2), reacting only against the CD4bs-directed IgG, were identified
and characterized. The P1 and P2 antibodies were shown to recognize the idiotype of the broadly neutralizing anti-CD4bs
human mAb b12. Both P1 and P2 Fabs were able to induce a strong anti-gp120 response in rabbits. Moreover, the rabbits’
sera were shown to neutralize two sensitive tier 1 strains of HIV-1 in an Env-pseudotype neutralization assay. In particular, 3/
5 rabbits in the P1 group and 1/5 in the P2 group showed greater than 80% neutralizing activity against the HXB2
pseudovirus. Two rabbits also neutralized the pseudovirus HIV-MN. Overall, these data describe the first anti-idiotypic
vaccine approach performed to generate antibodies to the CD4bs of the HIV-1 gp120. Although future studies will be
necessary to improve strength and breadth of the elicited neutralizing response, this proof-of-concept study documents
that immunogens designed on the idiotype of broadly neutralizing Abs are feasible and could help in the design of future
anti-HIV strategies.
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Introduction
Antibody-mediated neutralization is the mainstay of an effective
vaccine-induced protection from viral infections [1,2]. This
theoretical starting point is deeply challenged in the case of
persistent infections, as that caused by human immunodeficiency
type 1 virus (HIV-1) [3–5]. Indeed, unlike acutely infecting viruses,
HIV-1 is able to cope continuously with the human immune
system, thus successfully evading the antibody response. The main
targets of the anti-HIV-1 humoral response are the viral highly
variable surface glycoproteins, gp120 and gp41. It is not a case
that these proteins have represented the core of most anti-HIV-1
vaccines [6,7]. However all vaccines tested to date have not been
capable of stimulating a broadly neutralizing immune response,
the induced protection being limited only to a minor subset of
neutralization-sensitive HIV-1 isolates [6–11]. Indeed, these
approaches have suffered from the same limitations that do not
allow the mounting of an effective antibody response during the
course of natural infection, that is mainly the hypervariability of
HIV-1 immunodominant epitopes not fundamental for the viral
biology. Moreover, another important escape strategy of HIV-1 is
its ability to shield from the immune system several crucial regions
of its surface antigens, such as the region of gp120 capable of
binding the cellular receptor CD4 (CD4-binding site – CD4bs) [12–
15]. The high protective potential of the CD4bs and of other
functionally important conserved epitopes on HIV-1/gp120 has
been recently highlighted in slow progressor and long-term non-
progressor (LTNP) patients [16–18]. Indeed, several studies have
shown the protective role of broadly neutralizing antibody
subpopulations directed against epitopes present either on the
weakly immunogenic carbohydrate loaded ‘‘silent face’’ [16], or
on the CD4bs [17,18]. Overall, these findings suggest that the
antibody response to these epitopes could ultimately contribute,
together with T-cell response, to the efficient HIV-1 infection
control observed in LTNPs. The design of immunogens based on
these conserved epitopes, and capable of eliciting such a protective
response, could therefore be central to plan future prevention and
treatment strategies of HIV-1 infection [10,18–20]. Several
attempts are being made to design immunogens capable of
presenting to the immune systems these conserved epitopes. As far
as the CD4bs is concerned, all approaches using the whole gp120
protein have been of limited success due to the high flexibility of
native gp120. Indeed, gp120 can assume many decoy structures,
all recognized by the immune system, but all not exposing the
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neutralization [21–24]. An additional possibility is to use
chemically modified gp120 locked in the conformation assumed
by the protein when it binds the CD4, and therefore when it
exposes the CD4bs [25,26]. This approach has recently been
demonstrated to be superior in the capacity of eliciting
neutralizing antibodies to that based on the use of gp120 in its
native form [25]. Another rational approach is based on studying
the characteristics of the rare antibodies directed against the
CD4bs, thus backtracking to their corresponding epitopes. The
best characterized and the most potent anti-CD4bs monoclonal
antibody is b12 [27–30], whose crystal structure in its bound form
to gp120 has been recently defined [19]. Moreover, it has been
recently also evidenced that b12-like CD4bs-directed neutralizing
antibodies are produced in the course of the natural infection by
selected slow non-progressor patients [18]. The idiotype of these b12-
like antibodies could then be used to obtain molecular mimotopes
(linear peptides, conformational disulphide-linked peptides, anti-
idiotype antibodies), possibly representing the internal image of the
CD4bs. Several CD4bs-mimicking peptides have been reported to
date, but none of them has been able to stimulate a strong anti-
gp120 neutralizing antibody response in different animal models
[31–33]. Only in one case the immunization of rhesus macaques
with a pool of phage-displayed peptides mimicking conserved
HIV-1 epitopes (among which also the CD4bs) elicited a weak
neutralizing antibody response against a simian isolate (SHIV-
89.6PD) [34,35]. The use of epitope-mimicking peptides is based
on the assumption that the closer a peptide mimics the three-
dimensional structure of an epitope, the greater is the probability
that it could induce antibodies cross-reacting with the original
epitope. Notwithstanding, it is particularly difficult to obtain such
peptides when discontinuous conformational epitopes, as that
recognized by b12 on gp120, have to be mimicked [32]. A possible
solution to this problem could be to obtain conformational
mimotopes, as antibodies recognizing the idiotype of other
antibodies endowed with neutralizing activity against the pathogen
of interest [36].
Under this perspective, in this preliminary proof-of-concept
study we describe the generation of two anti-idiotype (AI) murine
antibodies recognizing human polyclonal anti-CD4bs IgG,
purified from LTNP. The selected AI molecules, putatively
mimicking the CD4bs, were shown to be specifically recognized
by b12 and to be capable of eliciting in rabbits a weak, though
detectable, neutralizing response against two tier 1 HIV
pseudoviruses [37].
Results and Discussion
Sequential serum samples from 4 LTNP patients were collected
over a period of 3 years; the LTNP shared the same clinical and
immunological profile, including HIV-1 seropositivity for at least 8
years, CD4 T-cell counts .500 cells/ml, absence of AIDS-related
opportunistic infections during the preceding 5 years, and serum
neutralizing activity against at least 2 different tier 1 isolates
belonging to different clades. The sera were pooled and the IgG
component was purified using a protein G-containing sepharose
column. Subsequently, the gp120 IIIB-binding fraction was eluted
using a method described elsewhere, with minimal modification
[38]. The cross-reactive CD4bs-directed antibodies were obtained
by saturating the column with soluble CD4, and passing the flow-
through, presumably enriched in CD4bs-directed antibodies, on a
second column containing gp120 MN. Fab fragments were
obtained from the anti-CD4bs IgG fraction using a commercial
kit, and subsequently used for immunization of Balb/c mice for
hybridoma generation. To verify the presence of possible AI
monoclonals directed against the anti-CD4bs fraction, the
supernatants of all hybridomas were screened in ELISA against
IgG-derived Fab preparations obtained from the sera of HIV-1-
negative patients. All hybridomas reacting against these control
Fab preparations were not considered further; whereas non-
reacting hybridomas were subsequently tested for reactivity on Fab
fragments derived from anti-CD4bs IgG. After this preliminary
screening, only two clones (P1 and P2) reacting specifically against
the anti-CD4bs fraction were taken into consideration for
subsequent testing.
To further characterize their binding specificity, P1 and P2 AI
clones were also tested (as Fab fragments) using a panel of anti-
gp120 human monoclonal antibodies (mAbs) directed against
crucial HIV-1 epitopes. In this assay, 100 ng each of the P1 and
P2 Fab were used as antigen in ELISA wells, and anti-gp120 mAbs
were tested for reactivity with P1 and P2. Recombinant gp120
(YU2 strain) and BSA were used as positive and negative controls
respectively. Importantly, P1 and P2 mAbs were recognized by
mAb b12, a broadly neutralizing human monoclonal antibody
directed against the gp120 CD4bs [27–30] (Figure 1A and 1B). Of
note, the non neutralizing anti-CD4bs mAb, F105, did not
recognize P1 and P2. Additionally, P1 and P2 were tested in a
competition ELISA for the ability to inhibit the binding of b12 to
immobilized gp120. Both AI mAbs were able to inhibit this
binding; in particular P1, at the highest concentration used, was
able to completely inhibit the binding of b12 to gp120 (Figure 1C).
P1 and P2 did not inhibit the binding to gp120 of any of the other
anti-gp120 mAbs used in this study (data not shown).
To confirm the AI nature of P1 and P2, the mAbs were used as
Fab fragments to immunize 5-week-old New Zealand female rabbits.
In particular, 4 groups of 6 rabbits each were immunized, with P1,
P2, an irrelevant mouse mAb (J1; negative control), or monomeric
gp120 IIIB (positive control). The animals were immunized
biweekly with 200 mg of each antigen, suspended in complete
Freund’s adjuvant (priming) or in incomplete Freund’s adjuvant
(two following boosts). After this schedule, the preimmune and
immune sera of each animal were titered in ELISA using
monomeric gp120. All of the P1-receiving rabbits featured a
strong anti-gp120 response, with titers ranging from 1:1600 to
1:25600; 5 out of the 6 P2-immunized rabbits showed a less
intense, albeit detectable, anti-gp120 response with titers ranging
from 1:800 to 1:6400. None of the J1-immunized control rabbits
showed any anti-gp120 response (Figure 2).
To evaluate whether the anti-gp120 positive rabbit sera had
HIV-1 neutralizing activity, the sera were tested using an Env
pseudovirus-based neutralization assay [18,39] against recombi-
nant viruses expressing the surface glycoproteins of two tier 1
HIV-1 strains: HXB2 and MN.3. In this triage study only tier 1
viruses were tested in order to evaluate even a minimal amount of
elicited neutralizing antibodies. None of the negative control sera
featured any neutralizing activity in terms of ID80 (reciprocal
serum dilution giving 80% neutralization) (Fig. 2b). Neutralizing
activity was demonstrated in 3 out of 5 rabbits in the P1 group
(samples from 1 of the rabbits were not available), and in one
rabbit of the P2 group; the neutralizing titers ranged from 1:20 to
1:150. Importantly, sera from 2 animals (one in the P1 and one in
the P2 group) featured a neutralizing activity against both
pseudoviruses (Figure 3).
Overall, we identified 2 putative CD4bs-mimicking AI mAbs
specifically recognizing a cross-reacting IgG polyclonal prepara-
tion purified from the sera of a cohort of HIV-1-infected LTNP
patients. Both mAbs were shown to react with the anti-CD4bs
human neutralizing mAb b12, and to elicit antibodies specifically
HIV-1 CD4bs-Mimicking mAbs
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tested in this study represent tier 1 viruses and much more work is
certainly needed before neutralization of tier 2 viruses may be
achieved, the reported data indicate that an anti-HIV-1 epitope-
based vaccine approach is possible. In addition, the present study
unambiguously documents that immunogens designed on the
idiotype of broadly neutralizing mAbs, if derived in the proper
way, could strongly help in the design of future anti-HIV-1
vaccines.
Materials and Methods
Purification of CD4-binding site-directed anti-gp120 IgG
from long-term non-progressor patients
All sera were derived from long-term non-progressor patients chosen
according to well defined criteria [16]. Each patient gave written
consent to use of the sera for research purposes, and the protocol
was approved by the San Raffaele Hospital’s ethics committee. All
different serum aliquots were pooled and the IgG fraction purified
by affinity chromatography. In brief, the pooled sera were diluted
with 10 volumes of phosphate buffered saline (PBS), and filtered
through 0.45 mm filters (Millipore Corporation; Bedford, MA). The
solution was then passed through a protein G-containing sepharose
column (Gammabind sepharose
TM, GE Healthcare Life Sciences,
UK). After a wash with 10 volumes of PBS, the bound IgG fraction
was eluted with 10 volumes of 0.1 M citric acid elution buffer
(pH 3), and rapidly neutralized with 1.5 M Tris-base.
Total anti-gp120 antibodies were then purified by affinity
chromatography using a gp120-Sepharose column. More in
details, 700 mg of a recombinant gp120 IIIB protein (Immuno-
Diagnostics Inc., Woburn, MA) diluted in 4 ml of coupling buffer
(100 mM NaHCO3; 500 mM NaCl; pH 8.2) were covalently
coupled to 4 ml of a CNBr-activated Sepharose resin (GE
Healthcare Life Sciences, UK). The solution was incubated
overnight at 4uC, and the unbound antigen was eliminated by
washing the resin with the coupling buffer. The resin was then
packed in a column, and washed with 10 volumes of 10 mM Tris
(pH 7.5). Further washings were subsequently performed with 10
Figure 1. Characterization of P1 and P2 binding features. (a) Recognition of P1 and P2 putative AI molecules by anti-gp120 mAbs. ELISA wells
coated with P1, P2, gp120 IIIB (YU2) as positive control, or BSA (negative control) were reacted with: I) four anti-CD4bs mAbs: b12 (1.4 mg/ml), F105
(1.5 mg/ml), 654-30D (1 mg/ml) and GP68 (1 mg/ml); II) two anti-V3 mAbs: F425 B4e8 (1.5 mg/ml) and 447-52D (1 mg/ml); III) one anti-C5 mAb: 670-30D
(0.4 mg/ml) and IV) one anti-CD4 induced epitope mAb 17b (1 mg/ml). All monoclonals were obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH. Interestingly, P1 and P2 were specifically recognized only by b12, the most potent mAb used in this
study in terms of neutralizing activity on primary isolates. The AI molecules were also tested with different preparations of standard IgG and with all
serum fractions discarded during the purification process of anti-CD4bs IgG, giving in all cases a negative result (data not shown). (b) Titration of b12
on P1, P2, gp120 and BSA. (c) Competition ELISA. The ability of P1 and P2 to inhibit the binding of b12 to immobilized gp120 was tested in a
competition ELISA. 96-well flat bottom plate wells were coated overnight at 4uC with HIV-1 YU2 gp120 (100 ng/well) and then blocked with 1% BSA-
PBS. b12 (1 mg/ml) and serial dilutions (from 10
25 Mt o1 0
212 M) of P1, P2 and J1 control mAb were added to the wells. b12 residual binding was
detected with enzyme-linked goat anti-human IgG.
doi:10.1371/journal.pone.0003423.g001
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assay. ELISA titers of preimmune (black) and immune (red) rabbits’ sera on gp120 IIIB (continuous line) and BSA (dotted line) after three
immunizations with the reported antigens. Data regarding the gp120 (positive control) and the J1 (negative control) groups are not reported, but for
all animals the titers were .1:12800 and ,1:25, respectively. Moreover, among the animals immunized with the mouse mAbs, no difference was
evidenced in terms of response elicited against the specific molecule used for the immunizations (data not shown).
doi:10.1371/journal.pone.0003423.g002
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(pH 8.8) and 10 volumes of 100 mM triethylamine (pH 11.2). The
column was finally equilibrated to pH 7.5 with 10 mM Tris
(pH 7.5). The purified serum antibodies were diluted 1:3 with
10 mM Tris (pH 7.5), and then consecutively passed for seven
times through the column at 4uC. The column was then washed
with 10 volumes of 10 mM Tris (pH 7.5), and the bound
antibodies were finally eluted with 10 mM glycine (pH 2.5). All
eluted fractions were then tested in ELISA, and those strongly
reacting against gp120 (O.D. 450 nm .2.0) were pooled.
In order to purify the antibodies putatively directed against the
CD4 binding-site (CD4bs) on gp120, the gp120 IIIB-sepharose
column was saturated with an excess of soluble CD4. The anti-
gp120 immunoglobulins, purified as described above, were then
passed through the column, and the flow-through was collected.
The flow-through fraction was then passed through another
gp120-Sepharose column, prepared exactly as described above,
but containing a recombinant gp120 MN. The bound fraction was
eluted as described above, and used for Fab fragments production
with a commercial kit (ImmunoPure Fab Preparation Kit - Pierce,
Rockford, IL), following manufacturer’s instructions.
BALB/c mice immunization, hybridoma generation and
selection of antibodies with putative anti-idiotype
features
After approval of all parts of the project involving animals by the
San Raffaele Hospital’s Institutional Animal Care and Use
Committee (I.A.C.U.C.), 5-week-old female BALB/c mice were
immunized intraperitoneally with 50 mg of purified anti-CD4bs
Fabs, resuspended in 0.5 ml of PBS and in 0.5 ml of complete
Freund’s adjuvant for the priming, and 0,5 ml of incomplete
Freund’s adjuvant for the subsequent boosts. A biweekly schedule
was followed for a total of 5 administrations. Three days after the
last boost the mice were sacrificed, and the spleen removed under
sterile conditions. The spleen cells were separated from the fibrous
component, and subsequently washed and resuspended in EMEM
(Invitrogen) added with penicillin (100 mIU/ml) and streptomycin
(100 mg/ml). As fusion partners for hybridoma generation, NS-1
myelomatous cells (ECACC # 85011427) were cultured in RPMI-
1640(Gibco)added with20%decomplemented bovine foetalserum
(BFS) (Gibco). The fusion was performed resuspending the spleen
cells and the NS-1 cells in 1 ml of a fusion medium (0.5 ml of EMEM,
0.025 dimethylsulfoxide and 0.475 ml of PEG1540). After 3 min-
utes, 5 ml of EMEM were added to the fusion medium; after
additional 3 minutes 7 ml of 20% decomplemented BFS-RPMI
were added to the medium. The cells were then centrifuged
(1200 rpm for 15’), and subsequently resuspended in 200 ml of
HAT selective medium (150.2 ml of RPMI-1640, 40 ml of
decomplementedBFS, 5.4 ml of a 7% sodiumbicarbonate solution,
135 mg/ml hypoxanthine, 40 mg/ml thymidine, 2 mg/ml aminop-
terin). The HAT selective medium was also added with penicillin
(100 mIU/ml),streptomycin(100 mg/ml),L-glutamine(2 mM) and
Amphotericin B (100 mg/ml). The cell suspension was incubated for
1 h at 36.5uC in an atmosphere of 5% CO2, and subsequently
200 ml were added in each well of ten 96-well Microtiter plates
(NUNC) for hybridoma growth. The plates were incubated as
above, and routinely checked for hybridoma growth. The super-
nantant of each hybridoma-containing well was tested in ELISA
against preparations of Fab fragments obtained from HIV-negative
patients. All hybridomas reacting against these preparations were
eliminated. Non-reacting hybridomas were tested for reactivity
against the preparation of Fab fragments used for the immunization
of mice. With this approach 2 Fabs, named P1 and P2, specifically
reacting on the anti-CD4bs fraction were evidenced.
Fab fragments were obtained for P1 and P2 by cloning the
genes coding for the light chain and the Fd fragment of the heavy
chain into an expression vector named pRBCaf [40]. Briefly, the
total mRNA was extracted from cultured cells and genes coding
for the light chain and Fd fragment were amplified by RT-PCR, as
previously described (CSH press, Phage display manual, ed.
Figure 3. Evaluation of P1 and P2-induced neutralizing activity in an Env-based pseudovirus assay. Data are reported as reciprocal of
serum dilutions giving 80% of pseudovirus neutralization (ID80). Neutralization data on Murine Leukemia Virus (MuLV) are also reported as control.
For sample shortage due to technical problems it was not possible to perform the assay with sera from rabbit # 8 (P1 group), and for rabbits # 15
and # 17 (P2 group) on MN and HXB2 pseudoviruses, respectively.
doi:10.1371/journal.pone.0003423.g003
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XhoI and SpeI (Roche) and then cloned into pRBCaf previously
digested with the same restriction enzymes. Similarly, the
amplified light chain gene was digested with SacI and XbaI
(Roche) and cloned into the pRBCaf light chain cloning site
previously digested with the same restriction enzymes.
Electrocompetent E. coli XL1-Blue (Stratagene) were then
transformed by electroporation with the vectors pRBCaf-P1 and
pRBCaf-P2, obtained as described above. Bacterial cultures from
transformed clones were used to produce P1 and P2 through
overnight induction with IPTG [isopropilb-D-tiogalattopiranoside
(Sigma), final concentration 1 mM], and subsequent cell lysis by
freezing/thawing cycles. Sonicated bacterial cultures were centri-
fuged and the supernatant recovered and tested in ELISA for
binding to human anti-CD4bs Fab fragments.
P1 and P2 Fab fragments purification
P1 and P2Fabwerepurified byimmuneaffinitychromatography
througha proteinG sepharosecolumn(Gammabind sepharoseTM,
GE Healthcare Life Sciences, UK) covalently bound to goat-anti-
mouse-(Fab)2 polyclonal IgG (PIERCE, Illinois). Briefly, bacterial
cultures were induced with IPTG (final concentration 1 mM) and,
after over night growth at 30uC, were centrifuged, the pellet
resuspended in PBS and then sonicated. Disrupted bacteria were
ultracentrifuged, the supernatant filtered and passed through the
sepharose column. The column was washed with 30 ml of PBS, and
the Fabs were eluted with 10 mL of elution buffer (H2O/ HCl
pH 2.2). The eluate was collected as 2 ml fractions quickly
neutralized with a basic solution (Tris-base 1 M, pH 9). The
absorbance of each fraction was measured at 280 nm in order to
evaluate the amount of purified Fab. The purity of the purified
protein was evaluated through SDS-PAGE. Purified Fab were
tested in ELISA for binding to human anti-CD4bs Fab.
Immunization of rabbits with P1 and P2
In order to evaluate the ability of the mouse AIs to induce an
anti-HIV-1/gp120 specific response, purified P1 and P2 were used
to immunize 5-week-old New Zealand female rabbits. In
particular, 4 groups of 6 rabbits each were formed (group A:
animals immunized with P1; group B: animal immunized with P2;
group C: animals immunized with an irrelevant mouse mAb (J1)
used as negative control; group D: animals immunized with
monomeric gp120 used as positive control). The animals were
immunized biweekly with 200 mg of each antigen, resuspended in
complete Freund’s adjuvant (Pierce, Rockford, IL) (priming) or in
incomplete Freund’s adjuvant (Pierce, Rockford, IL) (two following
boosts). The sera collected before and after this immunization
schedule were titered in ELISA using monomeric gp120 YU2.
Virus neutralization assays
HIV-1 Env pseudoviruses were prepared by cotransfecting 293T
cells with an Env expression plasmid containing a full gp160 gene
and an env-deficient HIV-1 backbone vector (pSG3DEnv), as
previously described [41]. Virus-containing culture supernatants
were harvested 2 days after transfection, centrifuged, filtered
through 0.45-mm filter and stored at 280uC. We used two Env-
pseudoviruses(HxB2andMN)toassessthe neutralizationactivityof
the rabbit sera. Envelope glycoproteins from murine leukaemia
virus (MuLV) were used as negative control envelope. Pseudovirus
neutralization was measured as a function of Tat-induced luciferase
reporter gene expression after a single round of infection in TZM-bl
cells, as previously described [18,39]. TZM-bl cells were obtained
from the NIH AIDS Research and Reference Reagent Program.
These cells express CD4, CXCR4 and CCR5 and contain an
integrated reporter gene for firefly luciferase under the control of
HIV-1 LTR. The level of viral infection was quantified by
measurement of relative luciferase units (RLU) that are directly
proportional to the amount of virus inputs. Briefly, 40 ml of virus
was incubated for 30 min at 37uC with serial dilutions of test serum
samples (10 ml) in duplicate wells of a 96-well flat bottom culture
plate. The final serum dilution was defined at the point of
incubation with virus supernatant. 10.000 TZM-bl cells were then
added to each well in a total volume of 20 ml and plates were
incubated overnight at 37uC in a 5% CO2 incubator. One set of
eight wells received mock antibody followed by virus and cells
(controls wells for virus entry) and a set of eight wells received cells
with mock virus (to control for luciferase background). Viral input
was set at a multiplicity of infection (MOI) that resulted in 100.000–
40.000 RLU. After over night incubation, 150 ml of fresh medium
was added to each well and incubated for 24 h at 37uCi na5 %
CO2 incubator. To determine RLU, cell culture medium was
aspirated from wells followed by addition of 50 ml of cell lysis buffer
(Promega, Madison, WI). 30 ml of cell lysate was transferred to wells
of a black Optiplate (Perkin–Elmer) for measurement of lumines-
cence using a Perkin–Elmer Victor-light luminometer that injects
50 ml ofluciferase substratereagent toeachwell just priortoreading
RLU. To determine the serum inhibitory dilution that resulted in a
80% reduction in RLU, serum neutralization curves were fit by
non-linear regression using a four-parameter hill slope equation
programmed into JMP statistical software (JMP 5.1, SAS Institute
Inc., Cary, NC). The results are reported as the serum
neutralization ID80, which is the reciprocal of the serum dilution
producing 80% virus neutralization.
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